UK Parliament / Open data

Streptococcus: Vaccination

Written question asked by Helen Hayes (Labour) on Thursday, 12 December 2024, in the House of Commons. It was due for an answer on Thursday, 12 December 2024 (named day). It was answered by Andrew Gwynne (Labour) on Thursday, 12 December 2024 on behalf of the Department of Health and Social Care.

Question

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support the development of a (a) safe and (b) effective Group B Streptococcus vaccine.

Answer

The UK Health Security Agency’s Vaccine Development and Evaluation Centre (VDEC) has been supporting the creation of a safe and effective maternal vaccine for Group B Streptococcus (GBS).

A maternal vaccine for GBS, which protects infants from both the early and late onset of the disease, will have a positive impact on infant mortality and morbidity. It will also lead to a sharp reduction in the use of antibiotics in neonatal units worldwide. By focusing on effectiveness, through advanced immune response evaluations, these efforts are accelerating the development of a reliable GBS vaccine that can protect vulnerable populations worldwide. Further information on how VDEC is supporting a GBS vaccine to prevent newborn deaths is available at the following link:

https://www.gov.uk/government/case-studies/vdec-is-supporting-a-gbs-vaccine-to-prevent-newborn-deaths.

Type
Written question
Reference
18575
Session
2024-25
Back to top